Swiss - Swiss Delayed Price. Currency in CHF
233.60-2.20 (-0.93%)
At close: 11:31 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close235.80
Bid232.50 x
Ask237.90 x
Day's Range232.50 - 236.60
52wk Range232.50 - 280.00
1y Target EstN/A
Market Cap196.68B
P/E Ratio (ttm)N/A
Avg Vol (3m)20,437
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • PR Newswire13 hours ago

    LabCorp is first US laboratory to offer molecular testing with new fully automated cobas 8800 system from Roche

    OTCQX: RHHBY) and Laboratory Corporation of America® Holdings (LabCorp®) (LH) announced today that the LabCorp Center for Esoteric Testing in Burlington, N.C., is the first site in the United States to offer commercial testing services with Roche's new cobas® 8800 system. The system automates the entire molecular diagnostics testing process—from specimen preparation and nucleic acid extraction/purification through polymerase chain reaction (PCR) amplification and detection—and is the first high-throughput molecular system to be approved by the FDA for CLIA moderately complex testing. LabCorp, the world's leading healthcare diagnostics company, is initially running hepatitis C viral load testing on the system and plans to add testing for HIV and hepatitis B virus in the coming months.

  • PR Newswire3 days ago

    Roche receives FDA approval for fully automated blood screening assay on the cobas® 6800/8800 Systems

    OTCQX: RHHBY) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the cobas® MPX test for use on the cobas® 6800 and 8800 Systems. The cobas® MPX test enables donor screening laboratories to apply the most advanced PCR-based diagnostic technology to the surveillance of donated blood and plasma in the United States, preventing the spread of Human Immunodeficiency Virus Groups 1 and 2 (HIV-1 and HIV-2), Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) through transfused blood products. "This approval reinforces our strong presence in donor screening, and underscores our ability to provide proven, robust technology for the testing of donated blood and blood products," said Uwe Oberlaender, Head of Roche Molecular Diagnostics.

  • PR Newswire4 days ago

    Spinal Muscular Atrophy Program Advances into Phase 2 Clinical Studies in SMA Patients with RG7916

    OTCQX: RHHBY) and the SMA Foundation (SMAF) initiated a Phase 2 study in pediatric and adult Type 2/3 SMA patients. The study, named SUNFISH, is a two-part study investigating the safety, tolerability and efficacy of RG7916, an oral small molecule survival motor neuron 2 (SMN2) splicing modifier. Initiation of the pivotal second part of the study is expected to begin in 2017 and will trigger a $20 million milestone payment to PTC from Roche.